This will not happen because of the Eisai agreement giving them right of first refusal. Therefore, an outside pharma would have to take over Eisai first. This leave Arena free and clear to develop new drugs involved with the GPCR receptor technology that they developed, patented, and license out for fees. It has been that activity that consisted on their bottom line in 2011 and earlier before the Eiasi deal was inked. That doesn't mean if someone tries and makes an offer that it won't pump up the share price.